Tiansheng Wang - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Tiansheng Wang

Showing results (171-180 of 173) with videos related to

Pageof 18

Sort By:

You have reached the last page of results.This site can display upto 173 results.

Nature Communications|January 2, 2025

Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney diseaseBrandon Zimmerman, Leslie A Dakin, Anne Fortier, et al.

Journal of Medicinal Chemistry|August 1, 2015

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune DiseasesLuc J Farmer, Mark W Ledeboer, Thomas Hoock, et al.

Journal of Medicinal Chemistry|July 15, 2014

Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2Michael P Clark, Mark W Ledeboer, Ioana Davies, et al.

Pageof 18

Search research articles

Showing results (171-180 of 173) with videos related to

Sort By:

Pageof 18

You have reached the last page of results.This site can display upto 173 results.

Nature Communications|January 2, 2025

Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney diseaseBrandon Zimmerman, Leslie A Dakin, Anne Fortier, et al.

Journal of Medicinal Chemistry|August 1, 2015

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune DiseasesLuc J Farmer, Mark W Ledeboer, Thomas Hoock, et al.

Journal of Medicinal Chemistry|July 15, 2014

Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2Michael P Clark, Mark W Ledeboer, Ioana Davies, et al.

Pageof 18